1. Home
  2. CRSP vs TKC Comparison

CRSP vs TKC Comparison

Compare CRSP & TKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$60.11

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Logo Turkcell Iletisim Hizmetleri AS

TKC

Turkcell Iletisim Hizmetleri AS

HOLD

Current Price

$6.71

Market Cap

5.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
TKC
Founded
2013
1993
Country
Switzerland
Turkey
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
5.2B
IPO Year
2016
2001

Fundamental Metrics

Financial Performance
Metric
CRSP
TKC
Price
$60.11
$6.71
Analyst Decision
Buy
Analyst Count
17
0
Target Price
$70.00
N/A
AVG Volume (30 Days)
1.5M
785.9K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
2.29%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,590,000.00
N/A
Revenue This Year
$1,603.19
$45.35
Revenue Next Year
$78.75
$30.18
P/E Ratio
N/A
$26.98
Revenue Growth
9169.85
N/A
52 Week Low
$30.06
$5.35
52 Week High
$78.48
$7.60

Technical Indicators

Market Signals
Indicator
CRSP
TKC
Relative Strength Index (RSI) 61.24 50.48
Support Level $58.40 $5.48
Resistance Level $60.40 $7.18
Average True Range (ATR) 3.03 0.11
MACD 1.16 -0.05
Stochastic Oscillator 86.78 15.86

Price Performance

Historical Comparison
CRSP
TKC

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About TKC Turkcell Iletisim Hizmetleri AS

Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.

Share on Social Networks: